Pilot Study on Safety and Effectiveness of Fecal Microbiota Transplant for Various Gut-Related and Immune Disorders

What this Trial Is About

Researchers are investigating the safety and effectiveness of fecal microbiota transplantation FMT for various disorders linked to gut microbiota imbalances, known as dysbiosis. These disorders include Crohns disease, ulcerative colitis, celiac disease, irritable bowel syndrome, metabolic syndrome, infections resistant to multiple drugs, and several others. FMT involves transferring feces from healthy donors to patients to restore balanced gut microbiota, and it has shown promise in previous studies for many conditions, though its use in typical clinical settings needs more evaluation. Participants in this study will receive fecal microbiota transplantation. The treatment will be applied across multiple disease groups such as Crohns disease, ulcerative colitis, diabetes, liver diseases, and infections including multidrug-resistant strains. The transplantation is done through various infusion methods suited to each patient. The study aims to assess FMTs impact on symptoms and monitor any treatment-related side effects over one year. During the study, participants clinical symptoms will be carefully tracked to measure improvement related to their specific condition. Researchers will also record any adverse events linked to the treatment using standardized criteria. The pilot study is designed to gather comprehensive safety and efficacy data on FMT in real-world clinical practice, with follow-up lasting one year to ensure thorough monitoring and evaluation.

Safety and Efficacy of Fecal Microbiota Transplantation